Meeting Report

Integrating Best Practices to Improve Outcomes in Relapsed/Refractory Multiple Myeloma

Presented by Amy E. Pierre,(1) MSN, ANP-BC, and Joshua Richter,(2) MD

From (1)Memorial Sloan Kettering Cancer Center, New York, New York; (2)Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, New York, New York

Presenters’ disclosures of conflicts of interest are found at the end of this article.


J Adv Pract Oncol 2020;11(3):306–311 | https://doi.org/10.6004/jadpro.2020.11.3.18 | © 2020 Harborside™


  

ABSTRACT

Amy E. Pierre, MSN, ANP-BC, and Joshua Richter, MD, break down the approved and emerging treatment options for relapsed/refractory multiple myeloma, including mechanisms of action, supporting clinical data, and associated adverse events, ​and discuss best practices for selecting and sequencing therapy​. 




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.